Mycophenolate sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534858

CAS#: 37415-62-6

Description: Mycophenolate sodium is an immunosuppressant.


Chemical Structure

img
Mycophenolate sodium
CAS# 37415-62-6

Theoretical Analysis

MedKoo Cat#: 534858
Name: Mycophenolate sodium
CAS#: 37415-62-6
Chemical Formula: C17H19NaO6
Exact Mass: 342.1079
Molecular Weight: 342.3228
Elemental Analysis: C, 59.65; H, 5.59; Na, 6.72; O, 28.04

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Mycophenolate sodium

IUPAC/Chemical Name: 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, monosodium salt, (4E)-

InChi Key: DOZYTHNHLLSNIK-JOKMOOFLSA-M

InChi Code: InChI=1S/C17H20O6.Na/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3;/h4,20H,5-8H2,1-3H3,(H,18,19);/q;+1/p-1/b9-4+;

SMILES Code: O=C([O-])CC/C(C)=C/CC1=C(O)C2=C(COC2=O)C(C)=C1OC.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 342.3228 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Int. 2015 May;28(5):508-15. doi: 10.1111/tri.12554. PMID: 25758949.

2: Hiramoto LL, Tedesco-Silva H, Medina-Pestana JO, Felipe CR. Tolerability of mycophenolate sodium in renal transplant recipients. Int J Clin Pharm. 2018 Dec;40(6):1548-1558. doi: 10.1007/s11096-018-0727-4. Epub 2018 Oct 9. PMID: 30302621.

3: Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13-58. doi: 10.2165/00003088-200746010-00002. PMID: 17201457.

4: Gabardi S, Tran JL, Clarkson MR. Enteric-coated mycophenolate sodium. Ann Pharmacother. 2003 Nov;37(11):1685-93. doi: 10.1345/aph.1D063. PMID: 14565799.

5: Budde K, Dürr M, Liefeldt L, Neumayer HH, Glander P. Enteric-coated mycophenolate sodium. Expert Opin Drug Saf. 2010 Nov;9(6):981-94. doi: 10.1517/14740338.2010.513379. PMID: 20795786.

6: Curran MP, Keating GM. Mycophenolate sodium delayed release: prevention of renal transplant rejection. Drugs. 2005;65(6):799-805; discussion 806-7. doi: 10.2165/00003495-200565060-00007. PMID: 15819592.

7: Isidori A, Loscocco F, Malerba L, Clissa C, Guiducci B, Visani G. Enteric- coated mycophenolate sodium: a new option for GHVD prophylaxis? Eur J Haematol. 2017 Apr;98(4):320-321. doi: 10.1111/ejh.12739. PMID: 26800509.

8: Ingle GR, Shah T. Enteric-coated mycophenolate sodium for transplant immunosuppression. Am J Health Syst Pharm. 2005 Nov 1;62(21):2252-9. doi: 10.2146/ajhp040380. Erratum in: Am J Health Syst Pharm. 2006 Mar 15;63(6):492. PMID: 16239415.

9: Midtvedt K, Bergan S, Reisæter AV, Vikse BE, Åsberg A. Exposure to Mycophenolate and Fatherhood. Transplantation. 2017 Jul;101(7):e214-e217. doi: 10.1097/TP.0000000000001747. PMID: 28346297; PMCID: PMC5482562.

10: Lazarevic VLj. Enteric-coated mycophenolate sodium could be an alternative to methotrexate for GVHD prophylaxis. Eur J Haematol. 2016 Sep;97(3):213-4. doi: 10.1111/ejh.12727. PMID: 26712567.

11: Sanford M, Keating GM. Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. Drugs. 2008;68(17):2505-33. doi: 10.2165/0003495-200868170-00007. PMID: 19016576.

12: Qureshi A, Scheinfeld N. Myfortic (mycophenolate sodium) delayed-release tablets. Dermatol Online J. 2008 Aug 15;14(8):4. PMID: 19061564.

13: Behrend M, Braun F. Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. Drugs. 2005;65(8):1037-50. doi: 10.2165/00003495-200565080-00001. PMID: 15907141.

14: Gardiner KM, Tett SE, Staatz CE. Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life? Drugs R D. 2018 Dec;18(4):271-282. doi: 10.1007/s40268-018-0254-8. PMID: 30426342; PMCID: PMC6277323.

15: Doukaki S, Platamone A, Alaimo R, Bongiorno MR. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus. J Dermatolog Treat. 2015 Feb;26(1):67-72. doi: 10.3109/09546634.2014.880395. Epub 2014 Feb 13. PMID: 24521072.

16: Kapoor K, Saha A, Kaur M, Dubey NK, Upadhyay AD. Mycophenolate Sodium for Children with Frequently Relapsing or Steroid Dependent Nephrotic Syndrome. Indian Pediatr. 2017 Oct 15;54(10):885-886. doi: 10.1007/s13312-017-1156-5. PMID: 29120340.

17: Zhang W, Ding C, Zheng S. Enteric-coated mycophenolate sodium: an update. Int J Clin Pract Suppl. 2014 Apr;(181):1-3. doi: 10.1111/ijcp.12399. PMID: 24673712.

18: Filler G, Buffo I. Safety considerations with mycophenolate sodium. Expert Opin Drug Saf. 2007 Jul;6(4):445-9. doi: 10.1517/14740338.6.4.445. PMID: 17688388.

19: Cooper M, Salvadori M, Budde K, Oppenheimer F, Sollinger H, Zeier M. Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. Transplant Rev (Orlando). 2012 Oct;26(4):233-40. doi: 10.1016/j.trre.2012.02.001. Epub 2012 Aug 3. PMID: 22863029.

20: Doycheva D, Zierhut M, Blumenstock G, Sobolewska B, Voykov B, Hohmann J, Spitzer MS, Deuter C. Mycophenolate sodium for the treatment of chronic non- infectious uveitis of childhood. Br J Ophthalmol. 2016 Aug;100(8):1071-5. doi: 10.1136/bjophthalmol-2015-306701. Epub 2015 Nov 13. PMID: 26567021.